Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Ea Pharma Co. Ltd. is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and are being prosecuted across 2 distinct art units. This distribution shows that the company's current patent filings are being evaluated in multiple technical environments, even with a small number of active cases. The use of 2 distinct art units suggests that the company's research covers different specialized sub-fields that require distinct examiner expertise.
The busiest examiner, MOORE, SUSANNA, is responsible for 1 pending office action, which accounts for 1 of the 2 pending office actions in the portfolio. Because there are 2 distinct examiners and 2 distinct art units for only 2 pending actions, each case is receiving a completely unique review path. This level of diversification suggests that the company's research in Biotechnology & Pharmaceuticals is not concentrated in a single niche. Practitioners should prepare for 2 entirely separate prosecution tracks, as each of the 2 pending office actions is being handled by a different examiner in a different art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOORE, SUSANNA | 1 | 68.1% | +31.6% |
| ROBINSON, MIKHAIL O'DONNEL | 1 | 59.2% | +42.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18624295 | METHOD FOR PRODUCING COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | MOORE, SUSANNA | — |
| 17433121 | MEDICINAL COMPOSITION HAVING EXCELLENT STABILITY | ROBINSON, MIKHAIL O'DONNEL | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18624295 | METHOD FOR PRODUCING COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | MOORE, SUSANNA | 1624 | DP | Final Rejection | — | Pending | Apr 02, 2024 |
| 17433121 | MEDICINAL COMPOSITION HAVING EXCELLENT STABILITY | ROBINSON, MIKHAIL O'DONNEL | 1627 | §112 | Non-Final OA | — | Pending | Aug 23, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial